ReviewNeuropsychiatric disease and treatment2026
Mini-Review: Allicin as a Potential Neuroprotective Compound in Neurological Disorders.
Review in Neuropsychiatric disease and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, allicin has received extensive attention in the field of neuroprotection. This mini-review summarizes the extraction, detection, synthesis, toxicity, novel drug delivery systems of allicin and its research progress in neurological diseases. We found that allicin can exert neuroprotective effects in Alzheimer's disease, Parkinson's disease, traumatic brain injury, cerebral ischemia-reperfusion injury, cerebral hemorrhage, and subarachnoid hemorrhage by inhibiting oxidative stress, neuroinflammation, and apoptosis, regulating mitochondrial function, and improving blood-brain barrier integrity. However, current studies are mostly limited to animal experiments and lack high-quality clinical research evidence. Additionally, the unstable chemical properties and low bioavailability of allicin have limited its clinical translation. In the future, more randomized controlled clinical trials should be conducted and new delivery systems should be developed to improve its stability and targeting. This mini-review aims to provide a theoretical basis for further research and application of allicin in neurological diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.